[go: up one dir, main page]

FI20070041A - Parannettu rokote Flavivirusinfektioiden vastaiseen immuunisointiin - Google Patents

Parannettu rokote Flavivirusinfektioiden vastaiseen immuunisointiin Download PDF

Info

Publication number
FI20070041A
FI20070041A FI20070041A FI20070041A FI20070041A FI 20070041 A FI20070041 A FI 20070041A FI 20070041 A FI20070041 A FI 20070041A FI 20070041 A FI20070041 A FI 20070041A FI 20070041 A FI20070041 A FI 20070041A
Authority
FI
Finland
Prior art keywords
immunization against
flavivirus infections
improved vaccine
against flavivirus
flavivirus
Prior art date
Application number
FI20070041A
Other languages
English (en)
Swedish (sv)
Other versions
FI118222B (fi
Inventor
Franz Xaver Heinz
Steven Allison
Christian Mandl
Christian Kunz
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0135294A external-priority patent/AT402897B/de
Priority claimed from AT0087195A external-priority patent/AT405607B/de
Application filed by Baxter Ag filed Critical Baxter Ag
Publication of FI20070041A publication Critical patent/FI20070041A/fi
Application granted granted Critical
Publication of FI118222B publication Critical patent/FI118222B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FI20070041A 1994-07-08 2007-01-17 Parannettu rokote Flavivirusinfektioiden vastaiseen immunisointiin FI118222B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AT0135294A AT402897B (de) 1994-07-08 1994-07-08 Verbesserte vakzine zur immunisierung gegen tbe-virusinfektionen sowie ein verfahren zu dessen herstellung
AT135294 1994-07-08
AT0087195A AT405607B (de) 1995-05-23 1995-05-23 Verbesserte vakzine zur immunisierung gegen tbe-virusinfektionen sowie ein verfahren zu dessen herstellung
AT87195 1995-05-23

Publications (2)

Publication Number Publication Date
FI20070041A true FI20070041A (fi) 2007-01-17
FI118222B FI118222B (fi) 2007-08-31

Family

ID=25594155

Family Applications (2)

Application Number Title Priority Date Filing Date
FI953371A FI117974B (fi) 1994-07-08 1995-07-07 Parannettu rokote immunisointiin TBE-virusinfektioita vastaan ja menetelmä sen valmistamiseksi
FI20070041A FI118222B (fi) 1994-07-08 2007-01-17 Parannettu rokote Flavivirusinfektioiden vastaiseen immunisointiin

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI953371A FI117974B (fi) 1994-07-08 1995-07-07 Parannettu rokote immunisointiin TBE-virusinfektioita vastaan ja menetelmä sen valmistamiseksi

Country Status (9)

Country Link
EP (2) EP0691404B1 (fi)
AT (2) ATE206459T1 (fi)
CZ (1) CZ282927B6 (fi)
DE (2) DE59509667D1 (fi)
DK (2) DK0869184T3 (fi)
ES (2) ES2165109T3 (fi)
FI (2) FI117974B (fi)
HU (2) HU219503B (fi)
RU (1) RU2150294C1 (fi)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258788B1 (en) 1997-11-20 2001-07-10 The United States Of America As Represented By The Secretary Of The Army DNA vaccines against tick-borne flaviviruses
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
CA2481479C (en) 2002-02-26 2012-12-11 Maxygen, Inc. Novel flavivirus antigens
WO2006067122A2 (en) 2004-12-20 2006-06-29 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
CA2608058C (en) 2005-05-12 2013-09-10 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
HUE027099T2 (hu) 2006-06-06 2016-08-29 Crucell Holland Bv Humán kötõmolekulák staphylococcus elleni ölõaktivitással és alkalmazásuk
EP2219671A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0284791B1 (de) * 1987-03-20 1995-05-03 IMMUNO Aktiengesellschaft DNA- und RNA-Moleküle des westlichen Subtyps des FSME-Virus, Polypeptide, die von diesen Molekülen codiert werden, und deren Verwendung
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
WO1992003161A1 (en) 1990-08-27 1992-03-05 The United States Of America, Represented By The Secretary, United States Department Of Commerce Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection
DK0584348T3 (da) 1992-03-11 2005-09-19 Powderject Vaccines Inc Genetisk vaccine mod immundefektvirusser

Also Published As

Publication number Publication date
HU219503B (hu) 2001-04-28
FI117974B (fi) 2007-05-15
ATE206459T1 (de) 2001-10-15
FI118222B (fi) 2007-08-31
CZ282927B6 (cs) 1997-11-12
RU2150294C1 (ru) 2000-06-10
DE59508988D1 (de) 2001-03-01
EP0691404B1 (de) 2001-01-24
FI953371A (fi) 1996-01-09
HU9903233D0 (en) 1999-11-29
EP0869184A3 (de) 1999-05-12
ATE198909T1 (de) 2001-02-15
EP0691404A2 (de) 1996-01-10
HU9501832D0 (en) 1995-08-28
EP0691404A3 (de) 1997-11-12
FI953371A0 (fi) 1995-07-07
EP0869184A2 (de) 1998-10-07
ES2155510T3 (es) 2001-05-16
CZ176995A3 (en) 1996-01-17
EP0869184B1 (de) 2001-10-04
HUT72395A (en) 1996-04-29
HU224199B1 (hu) 2005-06-28
DK0691404T3 (da) 2001-03-19
DE59509667D1 (de) 2001-11-08
DK0869184T3 (da) 2001-12-17
ES2165109T3 (es) 2002-03-01

Similar Documents

Publication Publication Date Title
CY1106350T1 (el) Εμβολιο φυματιωσης
FI20070041A (fi) Parannettu rokote Flavivirusinfektioiden vastaiseen immuunisointiin
DK0561890T3 (da) DNA ekspressionssystemer baseret på alphavira
ATE215124T1 (de) Rekombinante tetc-fusionsprotein enthaltene impfstoffzusammensetzungen
DK0757717T3 (da) Papillomavirusvacciner
ATE292685T1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
BR9605153B1 (pt) vacina de combinação, e, kit de vacinação.
HUT71847A (en) Dna molecules encoding aminopeptidase enzymes, vectors and transgenic cells containing dna molecules, immunogenic polypeptides encoding by dna molecules, vaccines against helminth infections containing these peptides and process for the preparation ...
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
DK606285D0 (da) Vaccine mod rabies samt fremgangsmaade til fremstilling deraf
DE69230671D1 (de) Impfstoffe gegen actinobacillus pleuropneumonie
DK0892054T3 (da) Clostridium perfringens-vaccine
DK457687D0 (da) Antigenisk aktive proteiner og peptider, og vacciner mod virus for felin peritonitis (fipv) med indhold af saadanne proteiner eller peptider
DK606088A (da) Rekombinant-dna-udtrykkelsesvektorer og dna-forbindelser, der koder for isopenicillin n synthetase
IL146191A0 (en) Viral expression vectors
ATE107695T1 (de) Virusvektor und rekombinante dns, die ein oder mehrere strukturelle proteine (ha,f und/oder np) eines morbillivirus kodieren.
KR970700770A (ko) Htra-프로모터를 사용하여 독성이 약화된 박테리아내에서 이종 단백질을 발현시키는 방법(expression of heterologous proteins in attenuated bacteria using the htra-promoters)
GB2295394A (en) Vaccine Compositions

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 118222

Country of ref document: FI

MM Patent lapsed